← 返回

乳腺癌中的 TIL(肿瘤浸润淋巴细胞):为什么了解它有用?

英文原题:Tumor Infiltrating Lymphocytes in Breast Cancer: Why Is It Useful to Know?

查看英文原题

Tumor Infiltrating Lymphocytes in Breast Cancer: Why Is It Useful to Know?

PubMed 2025/10/03(内容时间) Surg Pathol Clin

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

乳腺癌中的间质TIL(肿瘤浸润淋巴细胞)(sTILs)是一种易于评估的组织病理学生物标志物,已被证明在三阴性乳腺癌(TNBC)、HER2+和高危管腔型乳腺癌中具有稳健性和可重复性,并具有预后和预测价值。sTILs可在H&E染色切片上使用光学显微镜进行评估。sTILs还可预测新辅助治疗中化疗和免疫治疗的治疗反应,基线活检中较高的sTILs评分与较高的pCR率和更好的结局相关。sTILs在治疗降阶梯/优化策略以及免疫治疗患者选择中具有潜在作用。

展开英文摘要原文

Stromal tumor infiltrating lymphocytes (sTILs) in breast cancer is an easily evaluable histopathological biomarker that is shown to be robust and reproducible with prognostic and predictive value in triple negative breast cancer (TNBC), HER2+, and high-risk luminal breast cancer. sTILs can be assessed using a light microscope on H&E-stained slides.

sTILs also predict therapeutic response to chemotherapy and immunotherapy in the neoadjuvant setting, with higher sTILs score on baseline biopsies associated with higher pCR rates and better outcomes. sTILs have a potential role in therapy de-escalation/optimization strategies, and in the selection of patients for immunotherapy.

论文信息

作者
Maley SK、Khiroya R、Provenzano E、Salgado R
单位
NSABP Division of Pathology/ NRG Oncology Biospecimen Bank, 100 South Commons, Suite #120, Pittsburgh, PA 15212, USA. Electronic address: sai.maley@nsabp.org.United States
文献类型
综述
期刊
Surgical pathology clinics2025 Dec
原文标识
PubMed 41224415 · DOI 10.1016/j.path.2025.07.003